A Patient Perspective of the Impact of Medication Side Effects on Adherence: Results of a Cross-sectional Nationwide Survey of Patients with Schizophrenia

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2012 Mar 22

PMID 22433036

Citations 105

Authors

Marco DiBonaventura

Susan Gabriel

Leon Dupclay

Shaloo Gupta

Edward Kim

Affiliations

Soon will be listed here.

Abstract

Background: Antipsychotic medications often have a variety of side effects, however, it is not well understood how the presence of specific side effects correlate with adherence in a real-world setting. The aim of the current study was to examine the relationship between these variables among community-dwelling patients with schizophrenia.

Methods: Data were analyzed from a 2007-2008 nationwide survey of adults who self-reported a diagnosis of schizophrenia and were currently using an antipsychotic medication (N = 876). The presence of side effects was defined as those in which the patient reported they were at least "somewhat bothered". Adherence was defined as a score of zero on the Morisky Medication Adherence Scale. To assess the relationship between side effects and adherence, individual logistic regression models were fitted for each side effect controlling for patient characteristics. A single logistic regression model assessed the relationship between side effect clusters and adherence. The relationships between adherence and health resource use were also examined.

Results: A majority of patients reported experiencing at least one side effect due to their medication (86.19%). Only 42.5% reported complete adherence. Most side effects were associated with a significantly reduced likelihood of adherence. When grouped as side effect clusters in a single model, extra pyramidal symptoms (EPS)/agitation (odds ratio (OR) = 0.57, p = 0.0007), sedation/cognition (OR = 0.70, p = 0.033), prolactin/endocrine (OR = 0.69, p = 0.0342), and metabolic side effects (OR = 0.64, p = 0.0079) were all significantly related with lower rates of adherence. Those who reported complete adherence to their medication were significantly less likely to report a hospitalization for a mental health reason (OR = 0.51, p = 0.0006), a hospitalization for a non-mental health reason (OR = 0.43, p = 0.0002), and an emergency room (ER) visit for a mental health reason (OR = 0.60, p = 0.008).

Conclusions: Among patients with schizophrenia, medication side effects are highly prevalent and significantly associated with medication nonadherence. Nonadherence is significantly associated with increased healthcare resource use. Prevention, identification, and effective management of medication-induced side effects are important to maximize adherence and reduce health resource use in schizophrenia.

Citing Articles

A Clinically Oriented Review of New Antipsychotics for Schizophrenia.

Luca M, Luca A, Serretti A Neuropsychiatr Dis Treat. 2025; 20:2637-2649.

PMID: 39741904 PMC: 11687306. DOI: 10.2147/NDT.S501560.

Is there a relationship between psychiatrist's clinical assessment of medication non-adherence and treatment outcomes? Implications for practice.

Danzer G, Sugarbaker D, Zanello A, Barkin S, Cort D BMC Psychiatry. 2024; 24(1):925.

PMID: 39696040 PMC: 11656558. DOI: 10.1186/s12888-024-06298-7.

Pharmacist-led Si-care (schizophrenia care) model to improve medication adherence and symptom management in schizophrenia.

Cahaya N, Kristina S, Widayanti A, Green J Explor Res Clin Soc Pharm. 2024; 16:100544.

PMID: 39687446 PMC: 11647222. DOI: 10.1016/j.rcsop.2024.100544.

Side Effects of Psychotropic Medications Experienced by a Community Sample of People Living With Severe and Persistent Mental Illness.

Collins J, Wheeler A, McMillan S, Hu J, El-Den S, Roennfeldt H Health Expect. 2024; 27(6):e70122.

PMID: 39660682 PMC: 11632627. DOI: 10.1111/hex.70122.

Reasons for disengagement in first-episode psychosis - perspectives from service users and their caregivers.

Chua Y, Roystonn K, Pushpa K, Verma S, Tang C BMC Psychiatry. 2024; 24(1):788.

PMID: 39529004 PMC: 11555818. DOI: 10.1186/s12888-024-06190-4.

References

Goff D, Hill M, Freudenreich O . Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010; 71 Suppl 2:20-6. DOI: 10.4088/JCP.9096su1cc.04. View

Ritter P, Stewart A, Kaymaz H, Sobel D, Block D, Lorig K . Self-reports of health care utilization compared to provider records. J Clin Epidemiol. 2001; 54(2):136-41. DOI: 10.1016/s0895-4356(00)00261-4. View

Kendler K, Gallagher T, ABELSON J, Kessler R . Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996; 53(11):1022-31. DOI: 10.1001/archpsyc.1996.01830110060007. View

Kemmler G, Hummer M, Widschwendter C, Fleischhacker W . Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005; 62(12):1305-12. DOI: 10.1001/archpsyc.62.12.1305. View

Knapp M, Locklear J, Jarbrink K . Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Curr Med Res Opin. 2009; 25(7):1593-603. DOI: 10.1185/03007990903010623. View

Caqueo-Urizar A, Gutierrez-Maldonado J, Miranda-Castillo C . Quality of life in caregivers of patients with schizophrenia: a literature review. Health Qual Life Outcomes. 2009; 7:84. PMC: 2749816. DOI: 10.1186/1477-7525-7-84. View

Luft B, Taylor D . A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006; 7(13):1739-48. DOI: 10.1517/14656566.7.13.1739. View

Goldner E, Hsu L, Waraich P, Somers J . Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002; 47(9):833-43. DOI: 10.1177/070674370204700904. View

Raina P, Torrance-Rynard V, Wong M, Woodward C . Agreement between self-reported and routinely collected health-care utilization data among seniors. Health Serv Res. 2002; 37(3):751-74. PMC: 1434660. DOI: 10.1111/1475-6773.00047. View

10.

Morisky D, Green L, Levine D . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1):67-74. DOI: 10.1097/00005650-198601000-00007. View

11.

Weiden P, Mackell J, McDonnell D . Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2003; 66(1):51-7. DOI: 10.1016/s0920-9964(02)00498-x. View

12.

Messias E, Chen C, Eaton W . Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007; 30(3):323-38. PMC: 2727721. DOI: 10.1016/j.psc.2007.04.007. View

13.

Barbui C, Kikkert M, Mazzi M, Becker T, Bindman J, Schene A . Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009; 42(5):311-7. DOI: 10.1159/000232973. View

14.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

15.

Haro J, Salvador-Carulla L . The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006; 20(4):293-301. DOI: 10.2165/00023210-200620040-00003. View

16.

Burton S . Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract. 2005; 11(6):369-78. DOI: 10.1097/00131746-200511000-00003. View

17.

Pinto D, Robertson M, Hansen P, Abbott J . Good agreement between questionnaire and administrative databases for health care use and costs in patients with osteoarthritis. BMC Med Res Methodol. 2011; 11:45. PMC: 3095571. DOI: 10.1186/1471-2288-11-45. View

18.

Goossens M, Rutten-van Molken M, Vlaeyen J, van der Linden S . The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000; 53(7):688-95. DOI: 10.1016/s0895-4356(99)00177-8. View

19.

Kim E, Gupta S, Bolge S, Chen C, Whitehead R, Bates J . Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. J Med Econ. 2010; 13(2):185-92. DOI: 10.3111/13696991003723023. View

20.

Lacro J, Dunn L, Dolder C, Leckband S, Jeste D . Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63(10):892-909. DOI: 10.4088/jcp.v63n1007. View